GW Pharmaceuticals Plc American Depositary Shares
GWPH
GWPH was delisted on the 4th of May, 2021.
272 hedge funds and large institutions have $3.54B invested in GW Pharmaceuticals Plc American Depositary Shares in 2018 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 82 increasing their positions, 64 reducing their positions, and 41 closing their positions.
46% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 41
28% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 64
21% more capital invested
Capital invested by funds: $2.93B → $3.54B (+$605M)
7% more funds holding
Funds holding: 254 → 272 (+18)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less call options, than puts
Call options by funds: $128M | Put options by funds: $189M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$71.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$57.1M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$48.4M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$27.1M |
| 5 |
MCM
Marsico Capital Management
Denver,
Colorado
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$79.4M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$50.8M |
| 3 |
DM
Deerfield Management
New York
|
-$29.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$19.9M |
| 5 |
Barclays
London,
United Kingdom
|
-$18.9M |
GWPH Hedge Fund Activity: Q3 2018 in Review
272 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q3 2018, worth a combined $3.54B — up 21% from $2.93B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new GWPH positions and 41 closed out — a net gain of 19 holders — while 82 added to existing stakes and 64 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $71.3M. The largest seller was Scopia Capital Management, cutting an estimated $79.4M.
- 272 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q3 2018, up from 254 in Q2 2018.
- Funds reported $3.54B of GW Pharmaceuticals Plc American Depositary Shares stock for Q3 2018, up 21% quarter-over-quarter.
- 60 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q3 2018 and 41 closed out, a net change of +19 holders.
- The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q3 2018 was Citadel Advisors, an estimated $71.3M added.
- The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q3 2018 was Scopia Capital Management, an estimated $79.4M sold.
Based on aggregated 13F filings for Q3 2018.